Large-scale transient transfection of mammalian cells: a newly emerging attractive option for recombinant protein production.
Mammalian expression systems have an undisputed long-standing and very successful history for the generation of recombinant proteins, mainly as biopharmaceuticals. However, for use as 'tool proteins' in, e.g. assay development and screening, for structure elucidation and as antigens these expression systems were generally regarded as being cumbersome, tedious and expensive. This bias has largely been overcome with the very recent development of large-scale transient transfection (LST) approaches. Especially the HEK.EBNA expression system described here has contributed significantly to this success. The simplicity and speed of this approach compares well with expression trials using the widely applied Baculovirus/insect cell system. In addition, proteins generated in mammalian cells are usually correctly folded, fully processed and functionally active.
Geisse
Sabine
S
Novartis Institutes for BioMedical Research, Discovery Technologies/Biomolecules Production, 4002, Basel, Switzerland. Sabine.Geisse@novartis.com
Henke
Mario
M
D019149:Bioreactors; D002460:Cell Line; D003470:Culture Media; D019309:Epstein-Barr Virus Nuclear Antigens / Q000235:genetics*; D006801:Humans; D011994:Recombinant Proteins / Q000096:biosynthesis*; D014162:Transfection / Q000379:methods*
D003470:Culture Media; D019309:Epstein-Barr Virus Nuclear Antigens; D011994:Recombinant Proteins; C417029:EBV-encoded nuclear antigen 1